A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- li zhang
Sun Yat-sen University
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Tiantan Hospital of Capital Medical University
Beijing, Beijing Municipality, China
- Peking University Cancer Hospital
Beijing, Beijing Municipality, China
- Shunde Hospital of Southern Medical University
Foshan, Guangdong, China
- the First People'S Hospital of Shunde
Foshan, Guangdong, China
- Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China
- the First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
- Jiangmen Central Hospital
Jiangmen, Guangdong, China
- the Second Affiliated Hospital of Guilin Medical College
Gulin, Guangxi, China
- Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
- Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
- Nanyang Second General Hospital
Hanyang, Henan, China
- the First Affiliated Hospital of Xinxiang Medical College
Xinxiang, Henan, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technologe
Wuhan, Hubei, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
- Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
- Binzhou Medical University Hospital
Binzhou, Shandong, China
- Jinan Central Hospital
Jinan, Shandong, China
- Linyi Cancer Hospital
Linyi, Shandong, China
- Tianjin Medical University Cancer Institute Hospital
Tianjin, Tianjin Municipality, China
- Yunnan Cancer Hospital
Kunming, Yunnan, China
- Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
- Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Mar 2025
- Primary completion
- 31 Aug 2026
- Completion
- 31 Jul 2027
- Last update posted
- 5 Mar 2026
- Registered enrollment
- 121
- Registry id
- NCT06883630
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.